Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial
Start Date
11/6/2024
Completion Date
11/30/2027
Summary
This is a phase-III multi-center double-blind randomized controlled trial of 8,000 individuals undergoing a scheduled or prelabor cesarean delivery who are randomized to either adjunctive azithromycin prophylaxis or to placebo. Both groups also will receive standard of care preoperative antibiotics (excluding azithromycin). The primary endpoint is a maternal infection composite defined as any one of the following up to 6 weeks postpartum: endometritis, wound infection, abscess, septic thrombosis, sepsis, pneumonia, pyelonephritis and breast infection.
Detailed Description
This is a phase-III multi-center double-blind randomized controlled trial of 8,000 individuals undergoing a scheduled or prelabor cesarean delivery who are randomized to either azithromycin prophylaxis or to placebo. All participants will receive standard of care preoperative antibiotics. The primary objective is to evaluate in patients undergoing scheduled/prelabor cesarean if pre-incision adjunctive azithromycin prophylaxis reduces the risk of post-cesarean infections compared with placebo. Secondary objectives include 1) to assess the perinatal and maternal safety of pre-incision adjunctive azithromycin, 2) to evaluate whether adjunctive azithromycin prophylaxis reduces maternal and neonatal resource use outcomes compared with placebo, and 3) to evaluate whether adjunctive azithromycin influences maternal and neonatal infection with resistant organisms compared with placebo. Individuals will be randomized prior to the start of the cesarean to either 500mg of intravenous azithromycin or to placebo (normal saline). Maternal blood and cord blood will be collected on a subset of the population. Research staff will abstract maternal and neonatal outcomes following delivery and discharge from the hospital. A single maternal follow-up study visit at 6 weeks (4-8 weeks) postpartum will be scheduled to ascertain maternal and neonatal outcomes.
Eligibility Criteria
Age Range: No minimum to No maximum
Interventions
Azithromycin Injection
Placebo
Standard of Care Preoperative antibiotics
Conditions
Locations
University of Alabama - Birmingham
Birmingham, Alabama 35233
United States
Regents of the University of California San Francisco
San Francisco, California 94143
United States
Northwestern University
Chicago, Illinois 60611
United States
Columbia University
New York, New York 10032
United States
University of North Carolina - Chapel Hill
Chapel Hill, North Carolina 27599
United States
Duke University
Durham, North Carolina 27710
United States
Case Western Reserve University
Cleveland, Ohio 44109
United States
Ohio State University
Columbus, Ohio 43210
United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania 19104
United States
Magee Women's Hospital
Pittsburgh, Pennsylvania 15213
United States
Brown Univeristy
Providence, Rhode Island 02905
United States
Baylor College of Medicine
Houston, Texas 77030
United States
University of Texas - Houston
Houston, Texas 77030
United States
University of Utah
Salt Lake City, Utah 84132
United States